We constructed a metabolic disorder model using HL‐1 mouse atrial cardiomyocytes stimulated with a long chain saturated fatty acid, PA, to investigate the correlation between FGF19 and the cardiometabolic phenotype of patients with AF.21, 22. Here, FGF19 is linked to Other metabolic disease.